Not an actual patient.

Support and access for your practice

Ordering made easy for your practice

Order ELIGARD directly via TOLMARsync, by phone, or online through a majority of urology, oncology, and hospital GPO partners

Combat financial toxicity with Eligard

Cost burden is an important treatment consideration

ADT is the foundation of treatment for patients with advanced prostate cancer. As cancer care costs continue to rise, treatment affordability can impact access, adherence, and the overall patient experience. Financial toxicity is a real side effect of ADT treatment, as cancer care costs are projected to increase 34% between 2015 and 2030.²

MILLION AMERICANS

skipped treatment or cut spending on essentials to cover health care costs³

64^%

of cancer patients experience increased stress from medical debts and out-of-pocket costs⁴

Long-acting injectable therapy helps support treatment continuity without relying on daily adherence, while responsible pricing may help reduce financial barriers that can impact access to care

Tolmar is committed to keeping ELIGARD responsibly priced to ensure access across healthcare systems, providers, and patients

Consistently has one of the lowest costs* in the LHRH market⁵

The ONLY branded cancer therapy less than $500 with NO price* increase in over 10 years⁵

Supported by Tolmar's commitment to keep ADT responsibly priced for your patients

Backed by a strong body of clinical evidence, ELIGARD is a trusted choice that helps keep treatment costs as low as possible compared to other available ADT options⁵

*Price/costs represent wholesale acquisition cost (WAC).

^†Costs are standardized to represent one month of therapy.

When choosing a foundational therapy, the market-leading ADT ELIGARD offers an affordable option for patients

Support programs for your practice

Find support for your practice with these comprehensive programs from Tolmar

TOLMARsync: EXPECT MORE THAN JUST AN INVENTORY SOLUTION SYSTEM

TOLMARsync is an inventory solution system that optimizes patient management and practice capabilities

A digital platform designed to integrate directly into workflow to reduce administrative burden, TOLMARsync improves operational efficiency while ensuring patients always have access to treatment.

TOLMARsync helps to:

Improve patient tracking and organization with visibility into upcoming injections, overdue patients, and inventory needs

Simplified process through the online portal with an average response time of 4 hours

Enable reporting across your organization with support for billing reconciliation, patient navigation, and notifications

Support inventory management with tools for transfers, reconciliation, and reminders across practice locations

Sign up to request a representative or contact your current Tolmar representative to learn more

aPC Central arms healthcare professionals with knowledge, guidance, and support to care for advanced prostate cancer patients

aPC Central is a resource for advanced practice providers, nurses, and other healthcare professionals managing advanced prostate cancer, offering clinical information to support disease understanding and care planning.

At aPC Central, healthcare providers can find information about:

Diagnosing and staging advanced prostate cancer

Managing treatment planning across the patient journey

Mitigating common side effects

Preserving patient quality of life, and much more

Learn more at aPCCentral.com

Prostate Cancer 360 supports a comprehensive care approach to prostate cancer

Prostate Cancer 360 is an initiative created by a team of interdisciplinary experts that provides recommendations and tools to support more proactive, structured prostate cancer care and improve efficiency across your practice.

Prostate Cancer 360 helps you:

Support prevention and management of treatment side effects with clear guidance on assessment, monitoring, and care planning

Equip patients with essential information, including what to expect before and during treatment

Encourage patients to develop healthy lifestyle habits for overall well-being and quality of life

Learn more at ProstateCancer360.com

Tools and resources for your practice

Tolmar is here to support your practice with useful resources and downloads

Plan your patient’s treatment schedule with the dosing calculator

Use the Dosing Calculator tool to instantly see when your patient is due for their next dose by inputting the date of their latest treatment and prescribed dose.

Last injection date

Choose dose

1-month 3-month 4-month 6-month

Appointment date

Note

FDA approval of the ELIGARD product was based on studies utilizing a 28-day month dosing interval. This dosing calculator is for informational purposes only. Final dosing timing decision is up to the physician’s discretion.

Helpful videos, guides, and training sessions can help you with ELIGARD mixing & administration

MIXING & ADMINISTRATION VIDEO

MIXING & ADMINISTRATION GUIDE

Join Our Weekly Virtual Mixing & Administration Training Sessions

Virtual training sessions include a demonstration of the mixing and administration of ELIGARD. The clinical trainer will answer any questions you may have.

Patients who meet eligibility criteria may be able to receive ELIGARD via our Patient Assistance Program (PAP). Download and fill out the patient enrollment form to see if your patients may benefit.

Find support and resources for your patients and their care partners

ADT, androgen deprivation therapy; LHRH, luteinizing hormone-releasing hormone.

References: 1. Data on file. IQVIA data, Jan 2025-June 2026. Tolmar, Inc.; 2026. 2. Mariotto A, Enewold L, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304–1312. 3. West Health-Gallup Poll 2022. Accessed June 19, 2026. https://westhealth.org/news/estimated-98-million-americans-skipped-treatments-cut-back-on-food-gas-or-utilities-to-pay-for-healthcare/. 4. NIH National Cancer Institute. Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ^®)–Patient Version. NIH, Cancer.gov. Updated May, 29 2024. Accessed June 19, 2026. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq#_215_toc 5. Data on file. Tolmar, Inc.; 2026.

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD^® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.